Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma.
In the setting of interleukin-2 (IL-2) administration, tachycardias of ventricular origin are classified as serious, grade IV toxicities, necessitating the discontinuation of therapy. In this report, we describe a patient with renal cell carcinoma who experienced ventricular tachycardia while undergoing treatment with high-dose bolus IL-2. Prophylaxis with sotalol permitted the successful completion of his first cycle of treatment, without any recurrent rhythm disturbances.
Oleksowicz
L
L
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Escott
P
P
Leichman
G C
GC
Spangenthal
E
E
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013015:Sotalol / Q000627:therapeutic use*; D017180:Tachycardia, Ventricular / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D000970:Antineoplastic Agents; D007376:Interleukin-2; D013015:Sotalol